Bioventus (NASDAQ:BVS) Price Target Cut to $18.00 by Analysts at Canaccord Genuity Group

Bioventus (NASDAQ:BVS) had its target price dropped by analysts at Canaccord Genuity Group from $19.00 to $18.00 in a report issued on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity Group‘s price target suggests a potential upside of 36.88% from the company’s current price.

Other equities analysts have also issued research reports about the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $15.00 target price on shares of Bioventus in a research note on Monday, August 17th. Weiss Ratings raised shares of Bioventus from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, October 8th. Craig Hallum reissued a “buy” rating and set a $18.00 price target on shares of Bioventus in a research report on Thursday, August 6th. Finally, Barrington Research set a $18.00 price target on shares of Bioventus in a report on Thursday, August 6th. Six equities research analysts have rated the stock with a Buy rating. According to MarketBeat.com, Bioventus currently has an average rating of “Buy” and an average target price of $16.60.

Bioventus Trading Down 1.3%

Shares of NASDAQ:BVS opened at $13.15 on Tuesday. Bioventus has a 12-month low of $6.47 and a 12-month high of $15.89. The business’s fifty day simple moving average is $13.68 and its 200-day simple moving average is $10.90. The company has a market capitalization of $1.11 billion, a PE ratio of 17.08, a P/E/G ratio of 1.87 and a beta of 0.64. The company has a current ratio of 1.69, a quick ratio of 1.17 and a debt-to-equity ratio of 0.83.

Bioventus (NASDAQ:BVS) last released its quarterly earnings results on Monday, November 2nd. The company reported $0.17 EPS for the quarter, hitting the consensus estimate of $0.17. The firm had revenue of $142.44 million during the quarter. Bioventus had a return on equity of 28.08% and a net margin of 9.36%. As a group, equities research analysts predict that Bioventus will post 0.79 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bioventus

A number of large investors have recently bought and sold shares of BVS. Dimensional Fund Advisors LP lifted its stake in Bioventus by 14.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 873,138 shares of the company’s stock valued at $7,971,000 after acquiring an additional 107,930 shares during the period. Hillsdale Investment Management Inc. increased its stake in shares of Bioventus by 148.7% in the first quarter. Hillsdale Investment Management Inc. now owns 671,139 shares of the company’s stock worth $6,128,000 after acquiring an additional 401,230 shares during the period. Engine Capital Management LP purchased a new position in shares of Bioventus during the first quarter worth $2,876,000. Lazard Asset Management LLC raised its holdings in shares of Bioventus by 12.9% during the first quarter. Lazard Asset Management LLC now owns 305,517 shares of the company’s stock worth $2,789,000 after purchasing an additional 35,008 shares during the last quarter. Finally, Sei Investments Co. raised its holdings in shares of Bioventus by 160.7% during the first quarter. Sei Investments Co. now owns 289,648 shares of the company’s stock worth $2,644,000 after purchasing an additional 178,539 shares during the last quarter. Hedge funds and other institutional investors own 62.94% of the company’s stock.

Bioventus News Roundup

Here are the key news stories impacting Bioventus this week:

• Positive Sentiment: Bioventus reported third-quarter adjusted EPS of $0.17, matching analyst expectations and increasing from $0.15 a year earlier. The result marked the company’s sixth consecutive quarterly EPS beat or in-line result. Bioventus Matches Q3 Earnings Estimates
• Positive Sentiment: Management reaffirmed its fiscal 2026 adjusted EPS outlook of $0.75 to $0.79, broadly consistent with the $0.78 consensus estimate. The company’s earnings performance also benefited from debt paydown and lower interest costs. Bioventus Fiscal 2026 Outlook
• Neutral Sentiment: Third-quarter revenue was $142.44 million, while return on equity was 28.08% and net margin was 9.36%. Investors are assessing whether improving profitability can offset slower top-line growth. Bioventus Reports Third Quarter Financial Results
• Negative Sentiment: Bioventus cut fiscal 2026 revenue guidance to $590 million-$595 million from a level implied by the prior outlook, below the $604.6 million consensus estimate. The reduction signals weaker operational growth and was the main source of investor pressure. Bioventus Sales Miss and Outlook Cut
• Negative Sentiment: Commentary characterized earnings growth as being driven more by debt reduction than by underlying operations, raising concerns about the sustainability of profit improvement if revenue momentum remains limited. Bioventus Earnings Growth and Revenue Outlook

Bioventus Company Profile

Bioventus Inc is a medical device and biologics company focused on developing and commercializing products that support bone healing, joint health and surgical recovery. Its portfolio is designed to help healthcare professionals treat musculoskeletal conditions and improve patient outcomes through noninvasive therapies, injectable products and biologic solutions.

The company’s offerings include bone stimulation systems such as EXOGEN, which is used to support fracture healing, as well as injectable osteoarthritis treatments including DUROLANE and GELSYN-3.